Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
HKEX:1877
Holding HK:1877?
Track your performance easily
1877 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$9.17 - HK$24.60
Previous CloseHK$12.98
Volume941.80K
Average Volume (3M)1.70M
Market Cap
HK$27.97B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares OutstandingN/A
10 Day Avg. Volume2,224,387
30 Day Avg. Volume1,700,202
Standard Deviation0.18
R-Squared0.12
Alpha0.00447
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)8.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$14.90Price Target Upside14.79% Upside
Rating ConsensusHold
Number of Analyst Covering2
Shanghai Junshi Biosciences Co., Ltd. Class H News
PremiumCompany Announcements
Shanghai Junshi Secures Oncology License Agreement
PremiumCompany Announcements
Shanghai Junshi Biosciences’ UK Approval for Cancer Drug
PremiumCompany Announcements
Shanghai Junshi Biosciences Reduces Major Shareholders’ Stakes
PremiumCompany Announcements
Shanghai Junshi Biosciences Announces Q3 Results Briefing
PremiumCompany Announcements
Shanghai Junshi Biosciences Sees Key Shareholder Equity Shift
PremiumCompany Announcements
Shanghai Junshi Biosciences Optimizes Investment Strategy
PremiumCompany Announcements
Shanghai Junshi Biosciences to Boost Liquidity with Surplus Funds
PremiumCompany Announcements
Shanghai Junshi Biosciences Faces Board VacancyOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.41% Mutual Funds
― Other Institutional Investors
95.88% Public Companies and
Individual Investors
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$9.17 and its highest was HK$24.60 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Currently, no data Available
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Mar 27, 2025 which is in 125 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Oct 29, 2024. The company reported -HK$0.312 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.312.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 219,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of -HK$0.312 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.813%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
---
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.80%
12-Months-Change
Fundamentals
Return on Equity
-25.23%
Trailing 12-Months
Asset Growth
-3.25%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
---
1877 Stock 12 Month Forecast
Average Price Target
HK$14.90
▲(14.79% Upside)
Technical Analysis
BeiGene Ltd
―
CanSino Biologics, Inc. Class H
―
Guan Chao Holdings Limited
―
China XLX Fertiliser Ltd.
―
Best Analysts Covering 1877
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+10.50%
downgraded a sell rating 12 days ago
Copying Yang Huang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +10.50% per trade.
---